The International Stroke Trial and the Chinese Acute Stroke Trial were published in 1997 in the prestigious medical journal “The Lancet”. The International Stroke Trial and the Chinese Acute Stroke Trial were both published in the Lancet, a leading medical journal, and each conducted a large scale scientific clinical trial to determine the efficacy of aspirin, which is internationally recognized. “The International Stroke Trial is a trial of aspirin conducted in 467 hospitals in 36 countries with nearly 10,000 participants. It was observed after 14 days of aspirin treatment for cerebral infarction that it reduced the recurrence of cerebral infarction. The specific data for this efficacy were 11 fewer recurrences and 1 more cerebral hemorrhage per 1000 people taking it, for an overall benefit of 10 people. After 6 months of administration, there were 14 fewer recurrences and 14 fewer deaths from any cause per 1000 people. “In the China Acute Stroke Trial, a trial of over 20,000 aspirin cases in 413 hospitals, treatment for 4 weeks reduced recurrences and deaths by 13 per 1,000. From the above results, it can be seen that aspirin can reduce the recurrence of cerebral infarction and death when started early after cerebral infarction and taken for a long time. It also prevents and treats coronary heart disease and has been shown to be effective in similar trials. This data seems small in terms of effectiveness, but there is no drug in the world that exceeds aspirin in its efficacy in treating cerebrovascular disease. However, aspirin bleeding has side effects, mainly in the gastrointestinal tract, and bleeding is a given with this type of drug. For cerebrovascular patients, the overall picture is that most people get the benefit, but for each person specifically, you run the risk of side effects occurring at the same time, a risk that must be taken with aspirin for the prevention and treatment of cardiovascular disease.